Florian Lordick, Oncologist, Professor of Medicine at the University of Leipzig, Head of Medical Oncology, Director of the Comprehensive Cancer Center Central Germany, shared a post on LinkedIn:
“New insights from SPOTLIGHT and GLOW (ESMO Open)
Managing toxicity is not just supportive care—it directly affects outcomes. A new combined analysis from the phase III SPOTLIGHT and GLOW trials shows that nausea and vomiting with zolbetuximab + chemotherapy are most pronounced during the first infusion, but decline thereafter. Importantly, inadequate antiemetic control led to early discontinuation or reduced dose intensity in a relevant subset of patients, which was associated with inferior PFS and OS.
The key clinical message: proactive, guideline-concordant antiemetic prophylaxis (≥3 drug classes, including steroids) improves treatment adherence and helps patients derive the full survival benefit of zolbetuximab in CLDN18.2-positive gastric/GEJ cancer.
A strong reminder that optimal supportive care is an integral part of precision oncology.”
Title: Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies
Authors: K. Shitara, E. Smyth, F. Lordick, R. Pophale, C. Matney, M. Matsangou, G. Gourgioti, M. Oh, R. Ranganath, S.J. Klempner
Read the Full Article.
More posts about Florian Lordick.